Cipla Loses US Court Appeal In Pet Drug Patent Violation Case

Date : 06/07/2012 @ 8:46AM
Source : Dow Jones News
Stock : Sanofi (SAN)
Quote : 65.05  0.16 (0.25%) @ 11:35AM
Sanofi share price Chart

Cipla Loses US Court Appeal In Pet Drug Patent Violation Case

Sanofi (EU:SAN)
Historical Stock Chart

5 Years : From Feb 2013 to Feb 2018

Click Here for more Sanofi Charts.
   By Rumman Ahmed 

BANGALORE--Indian drug maker Cipla Ltd. (500087.BY) Thursday said it has lost an appeal in a U.S. court over a patent case related to a pet drug.

A lower U.S. court had in June last year ordered the seizure of pet drug PetArmor Plus made by Cipla and Velcera Inc. (VLCR) after ruling the drug violated a patent held by Merial, a unit of French giant Sanofi (SNY), covering Frontline Plus.

The U.S. court of appeals for the federal circuit in Washington D.C. affirmed the order of the district court, Middle District of Georgia, Cipla said in a statement to the stock exchanges.

The district court hasn't yet determined any financial implication of the patent infringement, Cipla said.

Cipla, which was manufacturing the drug on behalf of Velcera, said it was examining options for appealing against the latest order.

Write to Rumman Ahmed at

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V:us D:20180224 07:47:55